Genomics and Bioinformatics Group Genomics and Bioinformatics Group Genomics and Bioinformatics Group
Genomics and Bioinformatics Group

2016 Publication

Genomics and Bioinformatics Group
  Home
  Tools
  Molec Maps
  Members
  Contact
Publications
      2017
      2016
      2015
      2014
      2013
      2012
      2011
      2010
      2009
      2008
      2007
      2006
      2005
      2004
      2003
      2002
      2001
      2000
      1999
      Before 1999
      Selected
 

Cytidine deaminase deficiency reveals new therapeutic opportunities against cancer.
Mameri H, Bieche I, Meseure D, Marangoni E, Buhagiar-Labarch�de G, Nicolas A, Vacher S, Onclercq-Delic R, Rajapakse V, Varma S, Reinhold WC, Pommier Y, Amor-Gu�ret M.
Clin Cancer Res. 2016 Sep 6. pii: clincanres.0626.2016. [Epub ahead of print].
Read article in journal

Abstract:

PURPOSE:

One of the main challenges in cancer therapy is the identification of molecular mechanisms mediating resistance or sensitivity to treatment. Cytidine deaminase (CDA) was reported to be downregulated in cells derived from patients with Bloom syndrome, a genetic disease associated with a strong predisposition to a wide range of cancers. The purpose of this study was to determine whether CDA deficiency could be associated with tumors from the general population and could constitute a predictive marker of susceptibility to anti-tumor drugs.

EXPERIMENTAL DESIGN:

We analyzed CDA expression in silico, in large datasets for cancer cell lines and tumors, and in various cancer cell lines and primary tumor tissues using immunohistochemistry, PDXs, RT-qPCR, and western blotting. We also studied the mechanism underlying CDA silencing and searched for molecules that might target specifically CDA deficient tumor cells using in silico analysis coupled to classical cellular experimental approaches.

RESULTS:

We found that CDA expression is downregulated in about 60% of cancer cells and tissues. We demonstrate that DNA methylation is a prevalent mechanism of CDA silencing in tumors. Finally, we show that CDA-deficient tumor cells can be specifically targeted with epigenetic treatments and with the anticancer drug aminoflavone.

CONCLUSIONS:

CDA expression status identifies new subgroups of cancers, and CDA deficiency appears to be a novel and relevant predictive marker of susceptibility to antitumor drugs, opening up new possibilities for treating cancer.


Genomics and Pharmacology Facility
                Home Page Link to Center for Cancer Research Home Page Link to National Cancer Institute Home Page Link to National Institutes of Health Link to Department of Health & Human Services Home Page